BEGIN:VCALENDAR VERSION:1.0 BEGIN:VEVENT SUMMARY:Entrepreneurial Opportunities in Biotechnology DESCRIPTION;ENCODING=QUOTED-PRINTABLE:"How Strategic Alliances in Biotechnology Impact Venture's Valuation and Expedite Regulatory Approval" Caltech/MIT Enterprise Forum. With more than $84 billion in blockbuster drugs losing their US patent protection in 2007, Big Pharma is looking for expeditious ways to fill their pipeline with drugs capable of delivering attractive returns to their share holders while improving the health of millions of people across the world. One of the most popular models for accomplishing this objective is to partner with small biotech companies that have shown encouraging results at Pre-Clinical, Phase One and Phase Two of the FDA regulatory approval process. Steve Burrill, the CEO of Burrill & Company and the premier VC firm in this space, as well as the other participants will share their insights on how strategic partnerships help to raise company valuations and make them a more attractive target for acquisition. See http://events.entretech.org/com/event/oid/58/t/1/o/events DTSTART:20080405T080000 DTEND:20080405T090000 END:VEVENT END:VCALENDAR